检验医学 ›› 2024, Vol. 39 ›› Issue (4): 330-335.DOI: 10.3969/j.issn.1673-8640.2024.04.004

• 肿瘤免疫学标志物专题 • 上一篇    下一篇

结直肠癌患者外周血T淋巴细胞亚群与肿瘤进展的关系

郑慧, 陈颖秀, 叶绿茵, 卢仁泉, 郭林()   

  1. 复旦大学附属肿瘤医院检验科 复旦大学上海医学院肿瘤学系,上海 200032
  • 收稿日期:2023-10-25 修回日期:2023-12-12 出版日期:2024-04-30 发布日期:2024-05-07
  • 通讯作者: 郭 林,E-mail:guolin500@hotmail.com
  • 作者简介:郑 慧,女,1984年生,博士,副主任技师,主要从事临床检验工作。
  • 基金资助:
    国家自然科学基金面上项目(82072876)

Relationship between peripheral blood T lymphocyte subsets and tumor progression in patients with colorectal cancer

ZHENG Hui, CHEN Yingxiu, YE Lüyin, LU Renquan, GUO Lin()   

  1. Department of Clinical Laboratory,Shanghai Cancer Center,Fudan University; Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China
  • Received:2023-10-25 Revised:2023-12-12 Online:2024-04-30 Published:2024-05-07

摘要:

目的 探讨结直肠癌患者外周血T淋巴细胞亚群与肿瘤进展的关系。方法 选取2023年1—12月复旦大学附属肿瘤医院初诊结直肠癌患者100例(结直肠癌组),其中TNM分期Ⅰ期8例、Ⅱ期47例、Ⅲ期34例、Ⅳ期11例;有淋巴转移55例、无淋巴转移45例。以健康体检者80名作为正常对照组。采用流式细胞术检测CD3+T细胞百分比(CD3+%)、CD3+CD4+T细胞百分比(CD3+CD4+%)、CD3+CD8+ T细胞百分比(CD3+CD8+%)、CD3+CD4-CD8- T细胞[双阴性T细胞(DNT)]百分比(DNT%)、CD4+CD25+CD127low调节性T细胞百分比(CD4+Treg%)、CD3+PD-1+T细胞百分比(CD3+PD-1+%),计算CD4+/CD8+比值。同时检测肿瘤标志物[癌胚抗原(CEA)、糖类抗原(CA)19-9、CA72-4、CA50、CA242]。采用受试者工作特征(ROC)曲线评价各项指标判断结直肠癌患者淋巴转移的效能。结果 与正常对照组比较,结直肠癌组CD3+CD8+%显著升高(P<0.05),CD3+CD4+%、DNT%、CD4+/CD8+比值均显著降低(P<0.05);2个组之间CD3+%差异无统计学意义(P>0.05)。不同TNM分期的结直肠癌患者之间CD4+/CD8+比值、CD4+Treg%和CD3+PD-1+%差异均有统计学意义(P<0.05)。与无淋巴转移的结直肠癌患者比较,有淋巴转移的结直肠癌患者CD4+/CD8+比值显著降低(P<0.001),CD4+Treg%和CD3+PD-1+%显著升高(P<0.001)。ROC曲线分析结果显示,CD4+/CD8+比值、CD4+Treg%和CD3+PD-1+%单项检测和联合检测判断结直肠癌患者淋巴转移的曲线下面积(AUC)分别为0.762、0.775、0.765、0.825。以CEA、CA19-9、CA72-4、CA50、CA242任意1项阳性为肿瘤标志物阳性,TNM Ⅰ期患者肿瘤标志物均为阴性,Ⅱ期、Ⅲ期和Ⅳ期患者肿瘤标志物的阳性率分别为48.9%(23/47)、52.9%(18/34)、90.9%(10/11)。在TNM Ⅱ期和Ⅲ期患者中,肿瘤标志物阳性者CD4+/CD8+比值显著低于阴性者(P<0.001),CD4+Treg%显著高于阴性者(P<0.001),CD3+PD-1+%差异无统计学意义(P>0.05)。 结论 结直肠癌患者免疫抑制功能增强,T淋巴细胞亚群与肿瘤进展和肿瘤标志物表达密切相关。

关键词: T淋巴细胞亚群, CD4+/CD8+比值, CD4+调节性T细胞, 程序性死亡受体1, 结直肠癌

Abstract:

Objective To investigate the relationship between peripheral blood T lymphocyte subsets and tumor progression in patients with colorectal cancer. Methods Totally,100 newly diagnosed colorectal cancer patients in Shanghai Cancer Center of Fudan University from January to December 2023 were enrolled as colorectal cancer group. All the patients were classified into stage Ⅰ(8 cases),stage Ⅱ(47 cases),stage Ⅲ(34 cases) and stage Ⅳ(11 cases) according to TNM stages. There were 55 cases with lymphatic metastasis and 45 cases without lymphatic metastasis. Totally,80 healthy subjects were enrolled as healthy control group. Flow cytometry was used to determine the percentages of CD3+T cells(CD3+%),CD3+CD4+T cells(CD3+CD4+%),CD3+CD8+T cells(CD3+CD8+%),CD3+CD4-CD8-T cells [double-negative T cells (DNT)](DNT%),CD4+CD25+CD127low regulatory T cells(CD4+Treg%),CD3+PD-1+T cells(CD3+PD-1+%),and the CD4+/CD8+ ratio was calculated. The tumor biomarkers,carcinoembryonic antigen(CEA),carbohydrate antigen(CA)19-9,CA72-4,CA50 and CA242,were also determined. The efficacy of various indicators in determining lymphatic metastasis was evaluated by receiver operating characteristic(ROC) curve. Results Compared with healthy control group,the CD3+CD8+% in colorectal cancer group was increased(P<0.05),while the CD3+CD4+%,DNT% and CD4+/CD8+ ratio were decreased(P<0.05). There was no statistical significance in CD3+% between the 2 groups(P>0.05). There was statistical significance in CD4+/CD8+ ratio,CD4+Treg% and CD3+PD-1+% among colorectal cancer patients with different TNM stages(P<0.05). Compared with colorectal cancer patients without lymphatic metastasis,colorectal cancer patients with lymphatic metastasis showed a decrease in CD4+/CD8+ ratio(P<0.001),while CD4+Treg% and CD3+PD-1+% were increased(P<0.001). The area under curve(AUC) for single and combined determinations of CD4+/CD8+ ratio,CD4+Treg% and CD3+PD-1+% to determine lymphatic metastasis in colorectal cancer patients were 0.762,0.755,0.765 and 0.825,respectively. If taking any one of CEA,CA19-9,CA72-4,CA50 or CA242 positive as tumor biomarker positive,the patients for TNM stage Ⅰ were all negative,while the positive rates for stage Ⅱ,Ⅲ and Ⅳ were 48.9%(23/47),52.9%(18/34) and 90.9%(10/11),respectively. In patients of TNM stage Ⅱ and Ⅲ,the CD4+/CD8+ ratio in tumor biomarker positive patients was lower than that in negative patients(P<0.001),and CD4+Treg% was higher than that in negative patients(P<0.001). There was no statistical significance in CD3+PD-1+%(P>0.05). Conclusions The patients with colorectal cancer have the enhancement of immunosuppressive function,and T lymphocyte subsets have relations with tumor progression and tumor biomarker expression.

Key words: T lymphocyte subset, CD4+/CD8+ ratio, CD4+ regulatory T cell, Programmed death-1, Colorectal cancer

中图分类号: